Description
THIS AMENDMENT IS TO DECREASE PO AWARD BY $14,096.55 AS PER SERVICE REQUEST FOR CLOSEOUT.
Base award description: AWARDED TO GENZYME GENTICS FOR SPECIAL ESOTERIC TESTING DONE. THESE TESTS ARE NOT PERFORMED IN HOUSE. DATE FROM 10-01-2011 THRU 09-30-2012.
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2011-10-03+$250,000= $250,000
- Mod P000012013-09-03-$14,097= $235,903
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2011-10-03 | +$250,000 | $250,000 | AWARDED TO GENZYME GENTICS FOR SPECIAL ESOTERIC TESTING DONE. THESE TESTS ARE NOT PERFORMED IN HOUSE. DATE FRO… |
| Mod P00001· CLOSE OUT | 2013-09-03 | −$14,097 | $235,903 | THIS AMENDMENT IS TO DECREASE PO AWARD BY $14,096.55 AS PER SERVICE REQUEST FOR CLOSEOUT. |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI X2XMAQLR9DA8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36E79724A0018 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2024 |
| 36C26124N0260 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $11,882 | FY2024 |
| 36C26023F0186 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $144,553 | FY2023 |
| 36C26223F0045 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $246,001 | FY2023 |
| 36C26223F0022 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $266,652 | FY2023 |
| 36C26222F0606 | 262-NETWORK CONTRACT OFFICE 22 (36C262) · 6505 · DRUGS AND BIOLOGICALS | $20,049 | FY2022 |
Other recipients under Q301 from 243-NETWORK CONTRACTING OFFICE 03 (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA24316P1654 | VERACYTE, INC. | 243-NETWORK CONTRACTING OFFICE 03 | $11,749 | FY2016 |
| VA24316P1048 | DATA INNOVATIONS LLC | 243-NETWORK CONTRACTING OFFICE 03 | $12,500 | FY2016 |
| VA24315C0137 | TRIANGLE MANIFOLD SERVICES, INC. | 243-NETWORK CONTRACTING OFFICE 03 | $11,700 | FY2015 |
| VA24315P2997 | VERACYTE, INC. | 243-NETWORK CONTRACTING OFFICE 03 | $0 | FY2015 |
| VA24315J2661 | ROCHE DIAGNOSTICS CORPORATION | 243-NETWORK CONTRACTING OFFICE 03 | $105,071 | FY2015 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24312P0498_3600_-NONE-_-NONE- · retrieved 2026-09-26.